darunavir has been researched along with Acquired Immunodeficiency Syndrome in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Leonis, G; Mavromoustakos, T; Megariotis, G; Papadopoulos, MG; Supuran, CT; Tzoupis, H | 1 |
| Akpomiemie, G; Christofides, N; Lalla-Edward, S; Machisa, M; Mokgethi, NO | 1 |
| Baldin, G; Borghi, V; Capetti, A; Ciccullo, A; Colafigli, M; Di Giambenedetto, S; Fabbiani, M; Farinacci, D; Lagi, F; Masini, M; Montagnani, F; Mussini, C; Panza, F; Rossetti, B; Sterrantino, G; Tumbarello, M | 1 |
| Espinoza, LA; Gonzales Zamora, JA | 1 |
| Abgrall, S; Arribas, JR; Barger, D; Barrufet, P; Braun, D; Caniglia, EC; Cardoso, SW; Chrysos, G; Costagliola, D; Gill, J; Gogos, C; Hauser, C; Hernán, MA; Hoyos, SP; Justice, A; Leyes, M; Lodi, S; Logan, R; Meyer, L; Moreno, S; Muga, R; Pacheco, A; Phillips, A; Porter, K; Reiss, P; Sabin, CA; Seng, R; Tate, J; van Sighem, A; Vandenhende, MA; Winston, A | 1 |
| Choi, JY; Kee, MK; Kim, SS; Kwon, OK; Oh, HR; Park, M; Rhee, JE | 1 |
| Angarano, G; Monno, L; Saracino, A; Tartaglia, A; Tinelli, C | 1 |
| Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J | 1 |
| Brogan, AJ; Martin, S; Mauskopf, J; Talbird, SE | 1 |
| Hodder, S; Jayaweera, D; Mrus, J; Ryan, R; Witek, J | 1 |
| Aberg, JA; De La Rosa, G; Falcon, R; Gupta, SK; Landay, A; Overton, ET; Ryan, R; Sax, PE; Tebas, P | 1 |
| Arribas, J; Hill, A; Moecklinghoff, C; Pulido, F | 1 |
| Arribas, JR; Clumeck, N; Hill, A; Moecklinghoff, C; Nelson, M; van Delft, Y | 1 |
| Ambrosioni, J; Calmy, A; Daou, S; Merkler, D | 1 |
| Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, PE | 1 |
| Maeda, K; Mitsuya, H | 1 |
2 review(s) available for darunavir and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Decompressive Craniectomy; Dideoxynucleosides; Female; Humans; Intracranial Hypertension; Lopinavir; Medication Adherence; Meningoencephalitis; Organophosphonates; Sulfonamides; Tenofovir; Treatment Outcome | 2013 |
Development of therapeutics for AIDS: structure-based molecular targeting.
Topics: Acquired Immunodeficiency Syndrome; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Darunavir; Drug Design; HIV Infections; HIV Protease Inhibitors; Humans; Molecular Structure; Sulfonamides | 2007 |
5 trial(s) available for darunavir and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
[Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2014 |
Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Canada; CD4 Lymphocyte Count; Cost-Benefit Analysis; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV-1; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Nitriles; Pyridazines; Pyrimidines; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; Viral Load; Young Adult | 2012 |
Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Protease Inhibitors; HIV-1; Humans; Male; Nitriles; North America; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sex Distribution; Sex Factors; Sulfonamides; Treatment Outcome; Viral Load | 2012 |
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Atazanavir Sulfate; Biomarkers; CD4 Lymphocyte Count; Darunavir; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2012 |
The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Female; HIV Protease Inhibitors; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Surveys and Questionnaires; Treatment Outcome; Viral Load | 2012 |
11 other study(ies) available for darunavir and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.
Topics: Acquired Immunodeficiency Syndrome; Diabetes Mellitus; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Hypertension; Molecular Dynamics Simulation; Protein Binding; Protein Conformation; Renin; Sodium-Glucose Transporter 2 Inhibitors; Thermodynamics | 2012 |
Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Darunavir; Female; HIV Infections; HIV-1; Humans; Lopinavir; Quality of Life; Ritonavir; South Africa | 2022 |
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; RNA; Viral Load | 2023 |
Sinus bradycardia induced by darunavir-ritonavir in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Bradycardia; Darunavir; Female; HIV Protease Inhibitors; Humans; Ritonavir | 2017 |
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Alkynes; Americas; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Darunavir; Europe; Female; HIV Protease Inhibitors; Humans; Leukoencephalopathy, Progressive Multifocal; Lopinavir; Male; Meningitis, Cryptococcal; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Toxoplasmosis | 2018 |
Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genotype; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation; Nitriles; Phenotype; pol Gene Products, Human Immunodeficiency Virus; Protein Precursors; Pyridazines; Pyrimidines; Recombination, Genetic; Republic of Korea | 2015 |
[Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Clinical Trials as Topic; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Sulfonamides; Viral Load | 2008 |
Both a protective and a deleterious role for the L76V mutation.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Pyridines; Pyrimidinones; Pyrones; Sulfonamides | 2009 |
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2010 |
No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Genotype; HIV Protease Inhibitors; Humans; Nucleosides; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viral Load | 2012 |
XVI International AIDS Conference: Part 2.
Topics: Acquired Immunodeficiency Syndrome; CCR5 Receptor Antagonists; Clinical Trials as Topic; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Ritonavir; Salvage Therapy; Sulfonamides | 2006 |